Midostaurin

CAS 120685-11-2 8 current records 1 historicalSmall Molecule

Who holds supplier records for Midostaurin? 8 organisations hold a current record for Midostaurin: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4), Italy (1) and Netherlands (1); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Midostaurin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/midostaurin

Reading the evidence

  • 8 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    4 of the 6 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Midostaurin expires 2 Dec 2030. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (8)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Midostaurin. Country is the organisation's recorded country, not necessarily the manufacturing site.

India4Italy1Netherlands1Country not recorded for 2
  • Dr. Reddy's Laboratories Ltd.
    Active DMF 35231, 34665 · latest filing Sept 2020
    India Company GMP cert on record
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Active DMF 36640 · latest filing Dec 2021
    Company GMP cert on record
  • CONCORD BIOTECH LTD
    Active DMF 34976 · latest filing Oct 2020
    India Company GMP cert on record
  • Hetero Labs Limited
    Active DMF 36606 · latest filing Dec 2021
    India Company GMP cert on record
  • HUBEI HONCH PHARMACEUTICAL CO LTD
    Active DMF 35562 · latest filing May 2021
    Company GMP cert on record
  • MSN Laboratories Private Limited
    Active DMF 34522 · latest filing Jan 2020
    India Company GMP cert on record
  • PROCOS SPA
    Active DMF 35281 · latest filing Nov 2020
    Italy Company GMP cert on record
  • TAPI NL BV
    Active DMF 35289 · latest filing Nov 2020
    Netherlands
Need Midostaurin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Midostaurin are no longer active. These show a past filing, not current supply.

Show all 1 historical record

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (3 listed products contain Midostaurin). The latest listed patent expires 2 Dec 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Midostaurin is a multi-targeted kinase inhibitor used in the treatment of acute myeloid leukemia and certain other hematological malignancies. It works by interfering with the action of FLT3 and other kinases involved in cancer cell proliferation.

Chemical identity

IUPAC name
N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
Canonical SMILES
C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
InChIKey
BMGQWWVMWDBQGC-IIFHNQTCSA-N
Synonyms
Rydapt API, cgp 41251, cgp-41251, n-benzoylstaurosporine, nsc-656576, nvp-pkc412, pkc 412, pkc-412, rydapt

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Receptor Tyrosine Kinase Inhibitors

Therapeutic areas

OncologyHematology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Midostaurin?

8 organisations hold an active US FDA Type II Drug Master File or a CEP for Midostaurin: Dr. Reddy's Laboratories Ltd. (India), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD, CONCORD BIOTECH LTD (India), Hetero Labs Limited (India), HUBEI HONCH PHARMACEUTICAL CO LTD, MSN Laboratories Private Limited (India), PROCOS SPA (Italy) and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Midostaurin Drug Master Files are active?

Dr. Reddy's Laboratories Ltd. (DMF 35231, 34665), CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD (DMF 36640), CONCORD BIOTECH LTD (DMF 34976), Hetero Labs Limited (DMF 36606), HUBEI HONCH PHARMACEUTICAL CO LTD (DMF 35562), MSN Laboratories Private Limited (DMF 34522), PROCOS SPA (DMF 35281) and TAPI NL BV (DMF 35289). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Midostaurin records mean?

1 organisation has only inactive Type II DMFs for Midostaurin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Midostaurin?

Yes. The latest patent listed for an approved US product containing Midostaurin expires 2 Dec 2030, across 3 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Midostaurin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Midostaurin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.